Rene Choi
Ophthalmology · Portland, ORNPI 1881038404
Payments from drug & device makers
Across 166 payments — averaging $2025.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eyepoint US, Inc.$177K
- Genentech, Inc.$144K
- AbbVie$10K
- Carl Zeiss Meditec, Inc.$1K
- Alimera Sciences, Inc.$1K
- Bausch & Lomb Americas Inc.$536
- plus $2K from 14 others
What the payments were for
- Consulting fees$12,78261%
- Travel & lodging$8124%
- Food & beverage$5,72727%
- Education$2261%
- Gifts$1,4597%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eyepoint US, Inc. | 22 | $177,380 |
| Genentech, Inc. | 8 | $143,926 |
| AbbVie(2 entities) | 32 | $9,546 |
| Carl Zeiss Meditec, Inc. | 1 | $1,459 |
| Alimera Sciences, Inc. | 19 | $1,302 |
| Bausch & Lomb Americas Inc. | 12 | $536 |
| Mallinckrodt Hospital Products Inc. | 23 | $485 |
| Genentech USA, Inc. | 13 | $461 |
| Coherus Oncology, Inc. | 9 | $357 |
| Regeneron Healthcare Solutions, Inc. | 10 | $268 |
| Sandoz | 6 | $155 |
| Rayner Intraocular Lenses Limited | 1 | $66 |
| Dutch Ophthalmic, USA | 1 | $66 |
| Apellis Pharmaceuticals, Inc. | 2 | $49 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 2 | $48 |
| Astellas Pharma US Inc | 1 | $35 |
| Novartis | 1 | $23 |
| Biogen | 1 | $17 |
| Eyevance Pharmaceuticals LLC | 1 | $14 |
| ANI Pharmaceuticals, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$336,207 in reported general payments places this provider in the 95th percentile of 248 ophthalmology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira(Cf) PenAdalimumab | 34 | $276,680 |
| Prednisolone Acetate | 117 | $6,042 |
| Difluprednate | 57 | $5,425 |
| Mycophenolate Mofetil | 43 | $4,714 |
| Brimonidine Tartrate | 35 | $1,713 |
| Atropine Sulfate | 31 | $1,101 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 66 | $1,053 |
| Ofloxacin | 106 | $1,048 |
| Ketorolac Tromethamine | 38 | $587 |
| Dorzolamide Hcl | 23 | $463 |
| Timolol Maleate | 13 | $281 |
| Prednisone | 29 | $256 |
| Methotrexate SodiumMethotrexate Sodium/Pf | 11 | $77 |
Paid to pharmacies, not to this prescriber.
Other ophthalmology in Portland
- Mark PennesiPortland$2.6M
- Richard DreyerPortland$712K
- Paul YangPortland$666K
- Richard WeleberPortland$277K
- Nieraj JainPortland$235K
- Martin BalishPortland$124K
- Aazim SiddiquiPortland$13K
- Richard StutzmanPortland$10K
- Matthew KaufmanPortland$8K
- Monia RedingPortland$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.